Abstract
Background
Neuroendocrine Neoplasms of the small intestine have been noticed more frequently over the past 35 years. They constitute about 25 % of all NENs and 29 % of all tumors of the small intestine. Due to the predominantly indolent nature and overall good prognosis, the benefit of surgical treatment is still debated.
Methods
In a retrospective study, data of 83 surgically treated patients with neuroendocrine neoplasms of the small intestine, 48 males and 35 females with a median age of 62 years (range 25–86 years) were analyzed. Patient data were documented in the MaDoc database for neuroendocrine tumors of the University Medical Center of Mainz. IBM SPSS Statistics 20 was used for statistical analysis. Kaplan–Meier survival curves and Log-Rank tests, censoring patients at the time of last follow-up, were used to compare the overall survival depending on potential prognostic factors (stage, grade, surgical treatment).
Results
At the time of diagnoses, the most common clinical symptoms were abdominal pain (n = 31, 37.3 %), bowel obstruction (n = 11, 13.3 %), bowel perforation and peritonitis (n = 3, 3.6 %), gastrointestinal bleeding (n = 9, 10.8 %), weight loss (n = 11, 13.3 %), and carcinoid syndrome (n = 27, 32.5 %). 65 patients (78.3 %) had lymph node metastasis and in 58 patients (69.9 %) distant metastasis were present. Segmental bowel resection (44) was the most common surgical procedure, followed by right hemi-colectomy (32) and explorative laparotomy (7). In most patients (78.9 %), lymphadenectomy (systematic/selective) was performed. The 5-year survival of patients who underwent a systematic or a selective lymphadenectomy differed significantly (82.2 vs. 40.0 %). The overall 3-, 5-, and 10-year survival rates were 88.2, 80.3, and 71.0 %, respectively.
Conclusion
Mesenteric lymph node metastases are almost invariably present and have significant impact on patients’ prognosis. Systematic lymphadenectomy prevents complications and improves the survival. Early surgical treatment should be the goal in order to prevent complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bilimoria KY, Bentrem DJ, Wayne JD et al (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249:63–71
Akerstrom G, Hellman P (2007) Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:87–109
Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762
Pape UF, Jann H, Muller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265
Jann H, Roll S, Couvelard A et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117:3332–3341
Norlen O, Stalberg P, Oberg K et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36:1419–1431. doi:10.1007/s00268-011-1296-z
Basson MD, Ahlman H, Wangberg B et al (1993) Biology and management of the midgut carcinoid. Am J Surg 165:288–297
Ahlman H, Wangberg B, Jansson S et al (1991) Management of disseminated midgut carcinoid tumours. Digestion 49:78–96
Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–783 discussion 783-775
Que FG, Sarmiento JM, Nagorney DM (2006) Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol 574:43–56
Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885–894
Akerstrom G, Hellman P, Hessman O et al (2005) Management of midgut carcinoids. J Surg Oncol 89:161–169
Landry CS, Brock G, Scoggins CR et al (2008) A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients. Am J Surg 196:896–903 discussion 903
Musholt TJ (2011) Extent of resection for neuroendocrine tumors of the small intestine. Chirurg 82:591–597
Scherubl H, Jensen RT, Cadiot G et al (2010) Neuroendocrine tumors of the small bowels are on the rise: early aspects and management. World J Gastrointest Endosc 2:325–334
Ohrvall U, Eriksson B, Juhlin C et al (2000) Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24:1402–1408. doi:10.1007/s002680010232
Landry CS, Lin HY, Phan A et al (2013) Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg 37:1695–1700. doi:10.1007/s00268-013-1918-8
Acknowledgments
We thank Novartis for sponsoring the development of the database Software MaDoc.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
No potential conflicts of interest to be announced.
Rights and permissions
About this article
Cite this article
Watzka, F.M., Fottner, C., Miederer, M. et al. Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis. World J Surg 40, 749–758 (2016). https://doi.org/10.1007/s00268-016-3432-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-016-3432-2